Psilocin as a Geroprotector: The 2025 Emory Aging Study
Published in npj Aging: human cells treated with psilocin survived over 50% longer, and mice treated from 19 months of age showed roughly 30% increased survival with improved coat and hair regrowth, alongside reduced p21, p16 and GADD45a. Relevant because age is the dominant risk factor for neurodegeneration — but mouse lifespan extension is among the most replication-fragile claims in biology, and late-life survival gain is not extended maximum lifespan.
A 2025 study from Emory University, published in *npj Aging*, reported that **psilocin** — the active metabolite of psilocybin — extended lifespan in cultured human cells and in aged mice. ## What was reported **In cells.** Human cells treated with psilocin survived more than 50% longer than untreated controls. **In mice.** Animals aged 19 months at treatment onset — roughly equivalent to 60–65 human years — showed about a 30% increase in survival, along with visible changes: improved fur quality, hair regrowth, and fewer white hairs. **Molecular markers.** Reduced expression of the senescence markers **p21** and **p16**, reduced **GADD45a** (a DNA-damage response signal), and increased markers associated with healthy proliferation. The proposed framing is a "psilocybin–telomere hypothesis", positioning psilocin as a possible **geroprotector** acting on cellular senescence pathways rather than on any single disease. ## Why it is relevant to the neurodegeneration question Age is the dominant risk factor for neurodegenerative disease. A compound genuinely acting on aging biology could be upstream-protective in a way that a disease-specific mechanism is not — which is a more interesting hypothesis than the direct plasticity argument in Psychedelics for Neurodegeneration: Huntington's, Dementia, and the Evidence Gap. ## Why to hold it loosely **Mouse lifespan extension is one of the most replication-fragile claims in biology.** The literature is littered with compounds that extended lifespan in one laboratory's mice and not in another's. Results are notoriously sensitive to strain, diet, housing, sex, the age at which treatment starts, and control-group husbandry — and effects frequently shrink or vanish under the standardised multi-site protocols designed to catch exactly this. Further specifics here: treatment beginning at 19 months tests late-life intervention, and a survival increase measured from that point is not the same as an increase in maximum lifespan. Coat and fur changes are visible and suggestive but are soft endpoints. And cell-culture longevity is a weak proxy for organismal aging. The appropriate status is **an interesting preclinical finding awaiting independent replication** — not evidence that psilocybin is a longevity intervention in humans. Compare the pattern in Longevity Influencer Misinformation Pattern: When Real Prevention Tips Smuggle in Anti-Aging Hype.